AbbVie's Allergan Aesthetics gains European clearance for trenibotulinumtoxinE, a faster-acting botulinum toxin with shorter duration than traditional formulations.
Allergan Aesthetics has secured CE marking for Boey (trenibotulinumtoxinE), positioning it as the first and only rapid-onset, short-duration neurotoxin approved in Europe for glabellar frown lines. The product's mechanism—faster diffusion kinetics and a narrower therapeutic window—differentiates it from established competitors like Botox and Dysport, which typically require 3–7 days for full effect.
Boey's clinical profile targets a specific market segment: patients seeking quicker cosmetic results and practitioners managing toxin-related complications or seeking alternative dosing strategies. The shorter duration (expected 8–10 weeks versus 12+ for traditional formulations) creates higher re-treatment frequency, which carries both revenue and patient-retention implications for practices.
First and only rapid-onset, short-duration neurotoxin approved in Europe for frown lines.
This approval follows Revance's earlier U.S. launch of DaxxifyTM (daxibotulinumtoxinA), which emphasizes longevity. Boey's speed-of-onset positioning occupies a different niche—one that may appeal to first-time patients or those managing asymmetry or overcorrection.
Source: original report ↗
Frequently asked questions
How fast does Boey work compared to Botox?
Boey achieves full effect in 3–7 days, the same timeline as traditional Botox and Dysport. However, Boey's faster diffusion kinetics mean patients may see initial results sooner within that window. The key differentiator is not onset speed but rather its shorter duration of 8–10 weeks versus 12+ weeks for standard formulations.
How long does Boey last?
Boey lasts approximately 8–10 weeks, making it the shortest-duration neuromodulator on the market. This shorter window means patients require re-treatment more frequently than with traditional botulinum toxins, which can increase practice revenue but also requires stronger patient retention strategies.
What is trenibotulinumtoxinE and why is it different?
TrenibotulinumtoxinE is the active ingredient in Boey, engineered with faster diffusion kinetics and a narrower therapeutic window than conventional botulinum toxins. This formulation profile makes it useful for managing toxin-related complications, asymmetry, or overcorrection, and appeals to practitioners seeking alternative dosing strategies.
Is Boey approved in the US?
Boey has received CE marking for European approval but has not yet been cleared by the FDA for the U.S. market. The approval positions it as the first rapid-onset, short-duration neuromodulator available in Europe for glabellar frown lines.
Who should consider Boey over Botox or Dysport?
Boey is ideal for first-time patients seeking quicker visible results, practitioners managing overcorrection or asymmetry, and patients who prefer shorter re-treatment intervals. Its 8–10 week duration also makes it a lower-commitment option for patients hesitant about longer-lasting effects.
How does Boey compare to Daxxify?
Boey and Daxxify occupy opposite market niches: Daxxify (daxibotulinumtoxinA) emphasizes longevity with extended duration, while Boey prioritizes rapid onset and shorter duration. Practices can use both to serve different patient preferences—Daxxify for patients wanting fewer treatments, Boey for those seeking flexibility and quicker results.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
